Aramchol arachidyl amino cholanoic acid: Phase IIa data

A double-blind, Israeli Phase IIa trial in 60 patients with NAFLD, including non-alcoholic steatohepatitis (NASH), showed that once-daily 300 mg oral Aramchol met the primary endpoint of reducing live...